Delayed
Nasdaq
12:41:46 2024-05-21 pm EDT
|
5-day change
|
1st Jan Change
|
1.02
USD
|
-1.92%
|
|
+2.05%
|
-18.40%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,674
|
765.8
|
92.18
|
72.9
|
62.5
|
-
|
-
|
Enterprise Value (EV)
1 |
1,458
|
601.3
|
-146
|
72.9
|
11.09
|
90.59
|
66.98
|
P/E ratio
|
-5.5
x
|
-4.92
x
|
-0.68
x
|
-0.64
x
|
-0.64
x
|
-0.69
x
|
-0.6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
11.6
x
|
9.28
x
|
19.1
x
|
-
|
EV / Revenue
|
-
|
-
|
-
|
11.6
x
|
1.65
x
|
27.7
x
|
-
|
EV / EBITDA
|
-25.5
x
|
-4.02
x
|
1.08
x
|
-0.61
x
|
-0.11
x
|
-0.95
x
|
-0.38
x
|
EV / FCF
|
-30.7
x
|
-4.92
x
|
1.6
x
|
-
|
-0.12
x
|
-1.08
x
|
-0.65
x
|
FCF Yield
|
-3.26%
|
-20.3%
|
62.7%
|
-
|
-830%
|
-92.7%
|
-154%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
56,034
|
56,347
|
56,898
|
58,317
|
60,094
|
-
|
-
|
Reference price
2 |
29.87
|
13.59
|
1.620
|
1.250
|
1.040
|
1.040
|
1.040
|
Announcement Date
|
3/23/21
|
2/24/22
|
3/15/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
6.288
|
6.735
|
3.271
|
-
|
EBITDA
1 |
-
|
-57.2
|
-149.4
|
-134.8
|
-119.7
|
-98.46
|
-95.27
|
-174.7
|
EBIT
1 |
-16.82
|
-58.04
|
-151.4
|
-137.1
|
-121.8
|
-102.2
|
-93.23
|
-157.5
|
Operating Margin
|
-
|
-
|
-
|
-
|
-1,937.5%
|
-1,517.95%
|
-2,850.47%
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-88.44
|
-151.1
|
-133.2
|
-112.7
|
-96.85
|
-90.9
|
-156.8
|
Net income
1 |
-
|
-88.44
|
-151.1
|
-133.2
|
-112.7
|
-93.39
|
-85.9
|
-136.8
|
Net margin
|
-
|
-
|
-
|
-
|
-1,791.87%
|
-1,386.69%
|
-2,626.25%
|
-
|
EPS
2 |
-3.220
|
-5.430
|
-2.760
|
-2.370
|
-1.950
|
-1.615
|
-1.497
|
-1.740
|
Free Cash Flow
1 |
-
|
-47.48
|
-122.2
|
-91.5
|
-
|
-92
|
-84
|
-103
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-1,366%
|
-2,568.28%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
7/31/20
|
3/23/21
|
2/24/22
|
3/15/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
1.221
|
1.864
|
0.917
|
2.286
|
2.52
|
1.525
|
1.475
|
1.6
|
1.25
|
1.25
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-26.87
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-62.41
|
-36.36
|
-33.53
|
-33.54
|
-33.68
|
-28.49
|
-32.17
|
-33.82
|
-27.34
|
-31.99
|
-21.8
|
-21.2
|
-23.37
|
-22.5
|
-24.25
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-2,333.58%
|
-1,725.75%
|
-3,688.66%
|
-1,196.15%
|
-1,269.6%
|
-1,429.51%
|
-1,437.29%
|
-1,460.42%
|
-1,800%
|
-1,940%
|
Earnings before Tax (EBT)
1 |
-62.33
|
-36.26
|
-32.9
|
-32.26
|
-31.78
|
-26.24
|
-29.74
|
-31.37
|
-25.32
|
-29.96
|
-19.85
|
-18.95
|
-24.9
|
-21.9
|
-23.75
|
Net income
1 |
-62.33
|
-36.26
|
-32.9
|
-32.26
|
-31.78
|
-26.24
|
-29.74
|
-31.37
|
-25.32
|
-29.96
|
-19.85
|
-18.95
|
-24.9
|
-21.9
|
-23.75
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-2,148.89%
|
-1,595.55%
|
-3,421.37%
|
-1,107.61%
|
-1,188.81%
|
-1,301.64%
|
-1,284.75%
|
-1,556.25%
|
-1,752%
|
-1,900%
|
EPS
2 |
-1.130
|
-0.6500
|
-0.5900
|
-0.5700
|
-0.5600
|
-0.4600
|
-0.5200
|
-0.5400
|
-0.4300
|
-0.5000
|
-0.3433
|
-0.3467
|
-0.3800
|
-0.3550
|
-0.3950
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/4/22
|
8/4/22
|
11/8/22
|
3/15/23
|
5/10/23
|
8/8/23
|
11/13/23
|
3/21/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
28.1
|
4.48
|
Net Cash position
1 |
216
|
165
|
238
|
-
|
51.4
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-0.2949
x
|
-0.0256
x
|
Free Cash Flow
1 |
-47.5
|
-122
|
-91.5
|
-
|
-92
|
-84
|
-103
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
9.57
|
4.26
|
0.58
|
-
|
2
|
3
|
3
|
Capex / Sales
|
-
|
-
|
-
|
-
|
29.7%
|
91.72%
|
-
|
Announcement Date
|
3/23/21
|
2/24/22
|
3/15/23
|
3/21/24
|
-
|
-
|
-
|
Last Close Price
1.04
USD Average target price
4.125
USD Spread / Average Target +296.63% Consensus |
1st Jan change
|
Capi.
|
---|
| -18.40% | 62.5M | | +41.50% | 54.04B | | +43.57% | 41.96B | | -1.26% | 41.92B | | -7.59% | 28.35B | | +12.19% | 26.35B | | -22.48% | 19B | | +7.83% | 13B | | +29.08% | 12.28B | | +24.94% | 12.19B |
Other Biotechnology & Medical Research
|